Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B-cells. Originally developed for the treatment of B-cell lymphomas, rituximab has become one of the most widely used therapeutic antibodies in medicine, with applications extending from hematological malignancies to a broad range of autoimmune disorders.
In the context of neurodegenerative diseases, rituximab represents an attempt to target the B-cell component of the immune system that may contribute to neurodegeneration in certain conditions. By depleting CD20-positive B-cells, the antibody reduces autoantibody production, antigen presentation, and inflammatory cytokine release—all mechanisms that may be relevant in conditions where immune dysregulation contributes to neuronal damage.
Rituximab exerts its therapeutic effects through multiple complementary mechanisms:
CD20 Expression:
- CD20 is a surface antigen expressed on most mature B-cells
- Expressed from pre-B-cell stage through mature B-cells
- Not expressed on plasma cells (which produce antibodies)
- This pattern allows B-cell depletion while sparing antibody-producing plasma cells
Antibody Structure:
- Chimeric antibody with murine variable regions and human IgG1 Fc
- Designed for optimal effector function
- Mediates complement activation and antibody-dependent cellular cytotoxicity
Mechanism:
- Rituximab bound to CD20 activates the classical complement pathway
- Formation of membrane attack complex (MAC)
- Direct lysis of B-cells
- Particularly effective against cells with high CD20 density
¶ Antibody-Dependent Cellular Cytotoxicity (ADCC)
Mechanism:
- Fc portion of rituximab engages Fcγ receptors on natural killer cells, macrophages, and neutrophils
- These effector cells destroy rituximab-coated B-cells
- ADCC is a major mechanism of B-cell depletion in vivo
Apoptosis Induction:
- Cross-linking of CD20 by rituximab can directly induce apoptosis
- Contributes to B-cell depletion independent of immune effector mechanisms
Function Modulation:
- May modulate B-cell receptor signaling
- Reduces B-cell activation and proliferation
MSA is a rapidly progressive neurodegenerative disorder characterized by parkinsonian, cerebellar, and autonomic features. Evidence of B-cell involvement has motivated investigation of rituximab:
Rationale:
- B-cells have been implicated in the pathogenesis of MSA
- Autoantibodies against neural antigens detected in some patients
- Glial pathology may have immune components
- Rationale for B-cell targeting
Clinical Evidence:
- Phase II trials have investigated rituximab in MSA
- Some studies showed benefit in motor symptoms
- Results have been variable across studies
- Larger controlled trials are needed
Outcomes:
- May slow disease progression in some patients
- Effects more pronounced in early disease stages
- Not yet established as standard treatment
PSP is a tauopathy characterized by tau accumulation in subcortical and brainstem regions. While primarily a proteinopathy, immune mechanisms may contribute:
Rationale:
- Microglial activation documented in PSP brains
- Possible B-cell involvement in disease pathogenesis
- Theoretical basis for immune modulation
Clinical Evidence:
- Limited trials of rituximab in PSP
- Mixed results across studies
- Some patients showed slowed progression
- Insufficient evidence for routine use
ALS involves progressive loss of motor neurons. Immune dysregulation, including potential autoimmune components, has been implicated:
Rationale:
- T-cell abnormalities in ALS
- Potential for autoimmune-mediated motor neuron damage
- Microglial activation contributes to neurodegeneration
Clinical Evidence:
- Trials of rituximab in ALS have been conducted
- Results have been generally negative
- No clear benefit demonstrated
- Not used clinically for ALS
Rituximab is established in the treatment of paraneoplastic neurological syndromes:
Conditions Treated:
- Paraneoplastic cerebellar degeneration (anti-Yo, anti-Hu)
- Limbic encephalitis (anti-Ma2, anti-Hu)
- Paraneoplastic encephalomyelitis
- Opsoclonus-myoclonus syndrome
Evidence:
- Multiple case series demonstrate efficacy
- Often used in combination with other immunotherapies
- Particularly useful when antibodies target intracellular antigens (where plasma cell-targeting therapies are less effective)
Response Rates:
- Variable depending on antibody type and timing
- Earlier treatment generally produces better outcomes
- May require repeated dosing
Rituximab has become a cornerstone treatment for autoimmune encephalitis with surface antibodies:
First-Line Treatment:
- Anti-NMDA receptor encephalitis
- LGI1 encephalitis
- CASPR2 encephalitis
- Other surface antibody syndromes
Evidence:
- Highly effective in preventing relapse
- Superior to steroids alone in some studies
- Often used after first-line (steroids, IVIG, plasma exchange) fails
- May be used upfront in severe cases
Dosing:
- Standard: 375 mg/m² weekly for 4 weeks
- Alternative: 1 g on day 1 and day 15
- Re-dosing for relapse prevention in some cases
Myasthenia Gravis:
- Used in refractory cases
- Particularly effective in anti-MuSK positive MG
- Reduces relapse rate
Chronic Inflammatory Demyelinating Polyneuropathy:
- Second-line treatment when conventional therapies fail
- Effective in some patients
Multiple Sclerosis:
- Not FDA-approved but used off-label in progressive forms
- Not as effective as for other autoimmune conditions
¶ Pharmacokinetics and Administration
- Half-life: Approximately 21 days (range 15-30 days)
- Volume of distribution: Similar to plasma volume
- Clearance: Through reticuloendothelial system
Standard Dosing (for autoimmune conditions):
- 375 mg/m² weekly for 4 weeks
- Or 1 g on day 1 and day 15
- Premedication with antihistamine, acetaminophen, and often corticosteroids
Premedication:
- Diphenhydramine 25-50 mg
- Acetaminophen 650-1000 mg
- Methylprednisolone 100 mg (in many protocols)
- Reduces infusion reaction risk
Timeline:
- Peripheral B-cell depletion begins within 2-3 weeks
- Nadir typically achieved by 1-2 months
- B-cells remain depleted for 6-12 months
- Reconstitution begins from bone marrow progenitors
Monitoring:
- CD19+ B-cell counts can be monitored
- Useful for timing re-treatment if needed
¶ Adverse Effects and Safety
Frequency: Most common adverse effect, especially with first infusion
Symptoms:
- Fever and chills
- Hypotension or hypertension
- Bronchospasm
- Nausea and vomiting
- Headache
- Rash
Management:
- Premedication as described
- Slower infusion rate for reactions
- Stop infusion for severe reactions
- Most reactions are manageable
Increased Infection Risk:
- Overall infection risk moderately increased
- Particularly respiratory and urinary tract infections
Hepatitis B Reactivation:
- Screen for HBV before treatment
- Prophylaxis for high-risk patients
- Can cause severe hepatitis if reactivated
Progressive Multifocal Leukoencephalopathy (PML):
- Rare but serious risk
- John Cunningham virus reactivation
- Risk higher in combination with other immunosuppressants
- Often fatal or severely disabling
- Requires prompt recognition if symptoms develop
Hypogammaglobulinemia:
- Can develop after repeated cycles
- May increase infection risk
- May require IVIG replacement in severe cases
Cardiac Effects:
- Rare cardiac arrhythmias reported
- Exacerbation of pre-existing heart failure
- Most relevant in patients with underlying cardiac disease
Other:
- Fatigue
- Musculoskeletal pain
- Rare cytopenias
- Tumor lysis syndrome (rare)
- Active severe infection
- Known hypersensitivity to rituximab
- Severe heart failure
- Pregnancy (relative, use only if benefit outweighs risk)
- Active malignancy (relative)
| Agent |
Target |
Mechanism |
Neurological Use |
| Rituximab |
CD20 |
Depletes B-cells |
AE, CIDP, MG, PND |
| Ocrelizumab |
CD20 |
Depletes B-cells |
MS (approved) |
| Ofatumumab |
CD20 |
Depletes B-cells |
MS (approved) |
| Belimumab |
BLyS |
Inhibits B-cell survival |
Lupus (not neuro) |
| Eculizumab |
C5 |
Complement inhibition |
NMOSD (approved) |
Ocrelizumab:
- Humanized anti-CD20
- Approved for multiple sclerosis
- Less immunogenic than rituximab
Ofatumumab:
- Fully human anti-CD20
- Subcutaneous administration
- Approved for MS
Obinutuzumab:
- Glycoengineered for enhanced ADCC
- Being studied in various autoimmune conditions
- Combining rituximab with other immunomodulatory agents
- Sequential therapies targeting different immune pathways
- Integration with conventional treatments